On December 8, 2022, Shuangcheng Pharmaceuticals Europe S.r.l closed the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.5 CNY | -2.83% | -10.28% | -26.76% |
05-07 | Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US | MT |
04-29 | Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.76% | 326M | |
+22.35% | 44.12B | |
+22.22% | 22.61B | |
+17.81% | 15.11B | |
+15.73% | 13.61B | |
+57.91% | 13.34B | |
-8.98% | 6.94B | |
-0.05% | 6.79B | |
+14.03% | 5.75B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- 002693 Stock
- News Hainan Shuangcheng Pharmaceuticals Co., Ltd.
- Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.